company background image
CYP logo

Cynata Therapeutics CHIA:CYP Stock Report

Last Price

AU$0.34

Market Cap

AU$60.2m

7D

9.8%

1Y

139.3%

Updated

13 Jun, 2024

Data

Company Financials +

Cynata Therapeutics Limited

CHIA:CYP Stock Report

Market Cap: AU$60.2m

CYP Stock Overview

Develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

CYP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Cynata Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cynata Therapeutics
Historical stock prices
Current Share PriceAU$0.34
52 Week HighAU$0.34
52 Week LowAU$0.10
Beta0.92
1 Month Change36.73%
3 Month Change97.06%
1 Year Change139.29%
3 Year Change-37.96%
5 Year Change-72.87%
Change since IPO-14.10%

Recent News & Updates

Recent updates

Shareholder Returns

CYPAU BiotechsAU Market
7D9.8%-1.5%-0.7%
1Y139.3%-0.5%8.2%

Return vs Industry: CYP exceeded the Australian Biotechs industry which returned -0.5% over the past year.

Return vs Market: CYP exceeded the Australian Market which returned 8.2% over the past year.

Price Volatility

Is CYP's price volatile compared to industry and market?
CYP volatility
CYP Average Weekly Movement11.0%
Biotechs Industry Average Movement11.4%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market3.2%

Stable Share Price: CYP's share price has been volatile over the past 3 months.

Volatility Over Time: CYP's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aKilian Kellywww.cynata.com

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.

Cynata Therapeutics Limited Fundamentals Summary

How do Cynata Therapeutics's earnings and revenue compare to its market cap?
CYP fundamental statistics
Market capAU$60.18m
Earnings (TTM)-AU$13.65m
Revenue (TTM)AU$2.40m

25.1x

P/S Ratio

-4.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CYP income statement (TTM)
RevenueAU$2.40m
Cost of RevenueAU$0
Gross ProfitAU$2.40m
Other ExpensesAU$16.04m
Earnings-AU$13.65m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.076
Gross Margin100.00%
Net Profit Margin-568.80%
Debt/Equity Ratio0%

How did CYP perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.